Registry of Lobbyists

Registration - In-house Corporation

Bioniche Life Sciences Inc. / Michael Berendt, CEO

Registration Information

In-house Corporation name: Bioniche Life Sciences Inc.
Responsible Officer Name: Michael Berendt, CEO 
Responsible Officer Change History
Initial registration start date: 2005-08-19
Registration status: Inactive
Registration Number: 881654-5006

Associated Communications

Total Number of Communication Reports: 55

Monthly communication reports in the last 6 months: 0

Version 3 of 30 (2006-09-21 to 2007-04-10)

Version 3 of 30 (2006-09-21 to 2007-04-10) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Bioniche Life Sciences Inc.
231 Dundas Street East
P.O. Box 1570
Belleville, ON  K8N 5J2
Canada
Telephone number: 613-966-8058  Ext.: 1254
Fax number: 613-966-6997  
Responsible officer name and position during the period of this registration: Graeme McRae, President & CEO  
Description of activities: Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide.
 
Parent: The corporation is not a subsidiary of any other parent corporations.
Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? Yes
End date of the corporation's last completed financial year: 2006-06-30
 
List of Government Funding
Government Institution Funding Received in Last Financial Year
Technology Partnerships Canada $8,457,743.00

B. Lobbyists Employed by the Corporation

Name: Leslie Dunlop
Position title: Vice President Corporate Counsel
Public offices held: No
 
Name: Cameron Groome
Position title: Executive Vice President Corporate and Strategic Development
Public offices held: No
 
Name: John Howes
Position title: Controller
Public offices held: No
 
Name: Graeme McRae
Position title: President and CEO
Public offices held: No
 
Name: Patrick Montpetit
Position title: Vice President Finance and Chief Financial Officer
Public offices held: No
 
Name: Nigel Phillips
Position title: Senior Vice President, Scientific Affairs and Chief Scientific Officer
Public offices held: No
 
Name: Jennifer Shea
Position title: Corporate Communications Manager
Public offices held: No
 
Name: Martin Warmelink
Position title: President Food Safety and President Animal Health
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Agriculture and Agri-Food Canada (AAFC), Canadian International Development Agency (CIDA), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Office of the Information and Privacy Commissioner (OIPC), Revenue Canada (RC)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Government Procurement, Industry, Intellectual Property, Internal Trade, International Trade, Science and Technology, Taxation and Finance
 
Subject Matter: Retrospective: Ongoing discussions relating to Technology Partnerships Canada funding.
Subject Matter: Prospective: Ongoing compliance with obligations of the Technology Partnerships Canada funding program.Potential discussions with various government departments relating to vaccine production.Ongoing discussions with Revenue Canada relating to taxation issues.
 

Details Regarding the Identified Subject Matter

Categories Description
Grant, Contribution or Other Financial Benefit Technology Partnerships Canada Program
Policy or Program Technology Partnerships Canada Program relating to the development and commercialization of an E. coli vaccine and to Mycobacterial Cell Wall Technologies.




Date Modified: